Zai Lab Ltd (NAS:ZLAB)

$ 25.3 1 (4.12%) Market Cap: 2.65 Bil Enterprise Value: 2.16 Bil PE Ratio: 0 PB Ratio: 3.73 GF Score: 78/100

Q3 2024 Zai Lab Ltd Earnings Call Transcript
Nov 12, 2024

$28.96 (-6.85%)

Earnings
Q2 2024 Zai Lab Ltd Earnings Call Transcript
Aug 07, 2024

$16.65 (-8.06%)

Earnings
Q4 2023 Zai Lab Ltd Earnings Call Transcript
Feb 28, 2024

$20.8 (-7.51%)

Earnings
Zai Lab Ltd at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Q3 2023 Zai Lab Ltd Earnings Call Transcript
Nov 08, 2023

$30.01 (+6.00%)

Earnings
Q2 2023 Zai Lab Ltd Earnings Call Transcript
Aug 08, 2023

$24.19 (-8.58%)

Earnings
Zai Lab Ltd Investor Day Transcript
Jun 20, 2023
Q1 2023 Zai Lab Ltd Earnings Call Transcript
May 10, 2023

$37.51 (+6.08%)

Earnings
Q4 2022 Zai Lab Ltd Earnings Call Transcript
Mar 02, 2023

$36.93 (-8.54%)

Earnings
Zai Lab Ltd at Citi BioTech C-Suite Fireside Chat Series (Virtual) Transcript
Feb 14, 2023
Zai Lab Ltd at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 Zai Lab Ltd Earnings Call Transcript
Nov 10, 2022

$30.39 (+6.37%)

Earnings
Zai Lab Ltd at Citi BioPharma Conference Transcript
Sep 08, 2022
Q2 2022 Zai Lab Ltd Earnings Call Transcript
Aug 10, 2022

$44.73 (-1.06%)

Earnings
Zai Lab Ltd at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022
Q1 2022 Zai Lab Ltd Earnings Call Transcript
May 11, 2022

$25.03 (-4.61%)

Earnings
Q4 2021 Zai Lab Ltd Earnings Call Transcript
Mar 02, 2022

$52.53 (-0.04%)

Earnings
Zai Lab Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Q3 2021 Zai Lab Ltd Earnings Call Transcript
Nov 10, 2021

$87.82 (+1.30%)

Earnings
Zai Lab Ltd Topline POC Data Readout of ZL-1102 Corporate Call Transcript
Oct 21, 2021
Zai Lab Ltd R&D Day (Virtual) Transcript
Sep 22, 2021
Zai Lab Ltd at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2021
Q2 2021 Zai Lab Ltd Earnings Call Transcript
Aug 10, 2021

$149.76 (-2.77%)

Earnings
Zai Lab Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Q1 2021 Zai Lab Ltd Earnings Call Transcript
May 10, 2021

$149.45 (-5.50%)

Earnings
Full Year 2020 Zai Lab Ltd Earnings Call Transcript
Mar 01, 2021

$162.02 (+9.83%)

Earnings
Zai Lab Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Zai Lab Ltd at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2020
Half Year 2020 Zai Lab Ltd Earnings Call Transcript
Aug 13, 2020

$81.29 (+2.06%)

Earnings
Zai Lab Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Zai Lab Ltd at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Zai Lab Limited - Special Call Transcript
Apr 08, 2020
Q4 2019 Zai Lab Ltd Earnings Call Transcript
Mar 19, 2020

$49.64 (+2.03%)

Earnings
Zai Lab Ltd at JPMorgan Healthcare Conference Transcript
Jan 14, 2020
Q2 2019 Zai Lab Ltd Earnings Call Transcript
Sep 03, 2019

$32.54 (-0.21%)

Earnings
Zai Lab Ltd and Incyte Corp to Discuss the Collaboration and License Agreement for INCMGA0012 in Greater China Call Transcript
Jul 02, 2019
Zai Lab Ltd at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Zai Lab Ltd Corporate Analyst Meeting Transcript
Apr 30, 2019
Q4 2018 Zai Lab Ltd Earnings Call Transcript
Mar 07, 2019

$28.55 (+2.48%)

Earnings

Zai Lab Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 01:40PM GMT

Release Date Price: $68.99 (-5.00%)

Transcript

Ziyi Chen

Goldman Sachs Group, Inc., Research Division - Equity Analyst

Good morning, everyone. Thank you for joining today's Zai Lab session at our Global Healthcare Conference. This is Ziyi Chen, China healthcare analyst at Goldman Sachs.

Today joining us are Zai Lab's Co-Founder, Chairperson and CEO, Dr. Samantha Du; CFO, Billy Cho; and Jonathan Wang, Head of BD and IR team. Thank you all for attending these sessions.

Questions & Answers

Ziyi Chen;Ying Du<

Goldman Sachs Group, Inc., Research Division - Equity Analyst

Just to start the session, here's one specific question that probably most investors will be highly interested is the impact of COVID-19. We actually start this question for each of the session. So could you please give us some thoughts on the impact on clinical trials, BD activities and also the commercial launch of ZEJULA, Optune in China in this environment, particularly in first quarter? And how we actually track the recovery of everything, gradually back to normal in May, June? So any thoughts on that?

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.